Free Trial!
Today’s Best Stocks To Trade! Click Here
From January 2005 to October 2007, an aggregate amount of 114727577 shares of POZN have been shorted for a total dollar value of $1,147,275,770.00. The POZN SqueezeTrigger price of $10.416 is the volume weighted average price that all shorts are short in shares of POZN. There is still approximately $55,446,586.98 of potential short covering in shares of POZN.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .
Pozen, Inc. - Common Stock (NASDAQ:POZN) POZEN Inc. (POZEN), incorporated on September 25, 1996, is a pharmaceutical company focused primarily on products for the treatment of acute and chronic pain and other pain-related conditions. Since inception, the Company has focused its efforts primarily on the development or regulatory approval of pharmaceutical products for the treatment of migraine. It is also exploring the development of product candidates in other pain-related therapeutic areas. POZEN is developing Trexima, which incorporates its MT 400 technology, which refers to its combinations of a triptan (5-hydroxytryptamine 1B/1D agonist) and a non-steroidal anti-inflammatory drug (NSAID). The Company has two PN product candidates in development that combine a proton pump inhibitor (PPI) with an NSAID in a single tablet, PN 100, a combination of lansoprazole and naproxen, and PN 200, a combination of omeprazole and naproxen.
The Company's third product candidate under this exploratory program, PA 325, a combination of a PPI and aspirin, is in formulation development. The Company submitted a special protocol assessment (SPA) to the United States Food and Drugs Administration (FDA), in February 2006, for its pivotal Phase III studies for PN 200. The Company filed an investigational new drug (IND) application with the FDA for an injectable lornoxicam formulation in May 2005, and during the year ended December 31, 2005, it initiated the first human studies with this formulation under its IND. These studies include a Phase I pharmacokinetic study, as well as two Phase II studies to evaluate lornoxicam for management of post-operative bunionectomy pain and the pain of migraine headache.
MT 400/Trexima
In May 2004, POZEN commenced a Phase III clinical program for Trexima. As part of the Phase III program, the Company has completed two Phase III pivotal trials designed to determine the effectiveness and safety of Trexima for the acute treatment of migraine, as well as to satisfy the requirements of the FDA's combination drug rule. In addition, the Company conducted a long-term, open-label safety study. Along with these program trials, GlaxoSmithLine (GSK) has funded to conduct pre-approval market support studies for Trexima. The Company filed an NDA for Trexima in August 2005, and the FDA accepted it for review in October 2005.
MT 100
In May 2004, POZEN received a not-approvable letter from the FDA with respect to its new drug application (NDA) for MT 100, which it had filed in July 2003. In September 2005, after an FDA advisory committee concluded that the potential risk of tardive dyskinesia associated with the use of metoclopramide, one of the components of MT 100, outweighed the risks of the MT 100 combination, the Company decided to discontinue further development of MT 100 in the United States. In November 2005, the Company received notification that the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) had granted them marketing approval for MT 100 in the United Kingdom, based on its market authorization application (MAA) for MT 100 submitted during the year December 31, 2002 to the MHRA.
MT 300
In December 2002, POZEN submitted to the FDA an NDA for approval of MT 300. In October 2003, the Company received a not-approvable letter from the FDA with respect to its NDA for MT 300. Subsequently, it submitted additional responses to the not approvable letter. POZEN is not conducting any clinical trials for MT 300.
The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly one billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
CONTACT: Thomas Ronk, CEO Tel: +1 800 715 9999 e-mail: Tom@SqueezeTrigger.com WWW: http://www.SqueezeTrigger.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
